BioCryst says oral drug works for HAE attacks by Phil Taylor Tuesday, September 4, 2018 BioCryst says its BCX7353 drug effectively treated acute hereditary angioedema attacks in a midstage trial, setting up a possible registration study.
BioCryst stockholders call off merger with Idera Pharmaceuticals by Conor Hale Wednesday, July 11, 2018 BioCryst’s shareholders voted down a proposal to merge with Idera Pharmaceuticals and form a combined rare disease company.
